On July 29, 2025 Harbour BioMed (HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, reported that it will present Phase II clinical data on its next-generation, fully human heavy-chain-only anti-CTLA-4 antibody, porustobart (HBM4003), in combination with tislelizumab, for the treatment of microsatellite stable (MSS) metastatic colorectal cancer (mCRC), at the ESMO (Free ESMO Whitepaper) Congress 2025, taking place October 17-21, 2025, in Berlin, Germany (Press release, Harbour BioMed, JUL 29, 2025, View Source [SID1234654612]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
MSS mCRC remains a therapeutic challenge with limited response to immune checkpoint inhibitors. Preclinical evidence supports the synergistic antitumor activity of CTLA-4 blockade combined with PD-(L)1 inhibition in mouse models. In this multicenter, open-label, Phase II study (NCT05167071), heavily pretreated non-liver metastatic MSS mCRC patients were enrolled. Preliminary efficacy and safety data will be presented in a poster session during the ESMO (Free ESMO Whitepaper) Congress 2025.
Details of the poster presentation are as follows:
Title: Efficacy and Safety of HBM4003, an anti-CTLA-4 Antibody, Combined with Tislelizumab in MSS Metastatic Colorectal Cancer: A Multicenter, Phase II Study
Presentation Number: 807P
Speaker: Frank Zheng
All accepted abstracts will be published online on the ESMO (Free ESMO Whitepaper) website.
About Porustobart (HBM4003)
Porustobart (HBM4003) is a next-generation, fully human heavy-chain-only anti-CTLA-4 antibody discovered and developed using the HCAb Harbour Mice platform. It is also the first fully human heavy-chain-only antibody which entered clinical development globally. Compared with conventional CTLA-4 antibodies, porustobart has unique, favorable properties, including significant Treg cell depletion and optimized pharmacokinetics for improved safety. Additionally, by enhancing antibody-dependent cellular cytotoxicity (ADCC), porustobart increases the potential to selectively deplete intratumoral Treg cells, helping to overcome the efficacy and toxicity bottleneck of current CTLA-4 therapies. Harbour BioMed has implemented a global development plan for multiple types of solid tumors with an adaptive treatment design for porustobart. Positive efficacy and safety data have been observed in the monotherapy trials targeting advanced solid tumors, as well as in combination trials with PD-1 inhibitors for melanoma, CRC, NEN and HCC.